FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for IBD

FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for IBD
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency "urges the companies to review all claims made for their products, including consumer testimonials, to ensure they are supported by competent and reliable scientific evidence," according to a press release. The FTC also warned that continuing to sell CBD products without such evidence could violate the FTC Act and result in legal action. The companies — which the FTC did not name — have been instructed to respond within 15 days to tell the agency what specific actions have been taken to address the FTC's concerns. "It is illegal to advertise that a product can prevent, treat, or cure human disease without competent and reliable scientific evidence to support such claims," the agency warned in its letters. CBD is one of the active compounds of the cannabis plant that has garnered interest in past years for the treatment of multiple health conditions. In contrast with other cannabis compounds, CBD has demonstrated to have anti-inflammatory and pain-relieving properties without any psychoactive effects. Despite the therapeutic potential of cannabidiol, there is scarce scientific evidence effectively demonstrating the safety and benefits of CBD-based products. In most cases, there haven't been enough well-controlled studies to make reliable scientific conclusions about CBD's efficacy, or lack thereof. According to the FTC, however, that has not stopped some companies — and these three in particular — from making unsubstantiated claims about the "benefits" of CBD. The three companies
Subscribe or to access all post and page content.